Intravesical mitomycin C (MMC) and MMC + cytosine arabinoside for non‐muscle‐invasive bladder cancer: a randomised clinical trial

OBJECTIVES: To compare the urinary pH, recurrence‐free survival (RFS), and safety of adjuvant intravesical therapy in patients with non‐muscle‐invasive bladder cancer (NMIBC) receiving mitomycin C (MMC) therapy and MMC + cytosine arabinoside (Ara‐C) therapy. PATIENTS AND METHODS: A total of 165 pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyata, Yasuyoshi, Tsurusaki, Toshifumi, Hayashida, Yasushi, Imasato, Yushi, Takehara, Kosuke, Aoki, Daiyu, Nishikido, Masaharu, Watanabe, Junichi, Mitsunari, Kensuke, Matsuo, Tomohiro, Ohba, Kojiro, Taniguchi, Keisuke, Sakai, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290455/
https://www.ncbi.nlm.nih.gov/pubmed/34383381
http://dx.doi.org/10.1111/bju.15571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290455/
https://www.ncbi.nlm.nih.gov/pubmed/34383381
http://dx.doi.org/10.1111/bju.15571

Ejemplares similares